The life science group focused on skin health reported robust financial results, with significant revenue growth and improved profitability, positioning the company for continued success.
The life science company reports that the commercialisation of its product with Croda is progressing as expected, though financial details remain confidential.
The life science company has signed an exclusive UK commercial agreement with Superdrug Stores to sell its AxisBiotix™ food supplements.
The healthcare company has announced a change in shareholding, with an investor increasing their stake in the business.
The life science group has completed a retail offering, raising £0.1 million.
The healthcare company is raising up to £0.62m through a retail offer, with the new shares priced at a small premium to the previous closing price.
The healthcare company has signed an exclusive UK deal with a major retailer and raised funds to support the launch and product development.
The life science company has appointed a new nominated adviser and sole broker.
The life science company has appointed a new Nominated Adviser and Sole Broker.
The healthcare company has announced changes to its major shareholdings.